466 Participants Needed

Bepranemab for Alzheimer's Disease

Recruiting at 130 trial locations
UC
Overseen ByUCB Cares
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing bepranemab, a new medication, to see if it can help people with early-stage Alzheimer's disease. The study focuses on individuals who are just starting to show symptoms or have mild symptoms. Bepranemab works by removing harmful proteins from the brain that are linked to Alzheimer's.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as atypical antipsychotics, opiates, opioids, benzodiazepines, barbiturates, hypnotics, or any medication with significant antihistamine or anticholinergic effects. If you are on these medications, you may need to stop them before participating.

Who Is on the Research Team?

UC

UCB Cares

Principal Investigator

001 844 599 2273 (UCB)

Are You a Good Fit for This Trial?

This trial is for people aged 50-80 with mild cognitive impairment or mild Alzheimer's, as defined by specific criteria. They must have a certain level of memory function and an informant who can report on their condition. Those with other cognitive conditions, recent experimental therapy use, or certain medication histories are excluded.

Inclusion Criteria

I am between 50 and 80 years old.
I have been diagnosed with early-stage Alzheimer's Disease.
My memory test score for recalling information was 85 or less.
See 5 more

Exclusion Criteria

You have health conditions that prevent you from having a PET scan.
I haven't used any experimental treatments in the last 6 months.
I have a condition affecting my thinking or memory not caused by Alzheimer's.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Double-blind Treatment

Participants receive either bepranemab or placebo to evaluate efficacy, safety, and tolerability

80 weeks

Open-label Extension

Participants may opt into continuation of treatment with bepranemab long-term

72 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

72 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Bepranemab
Trial Overview The study tests Bepranemab against a placebo to see its effects on dementia symptoms in Alzheimer's patients over 80 weeks. It focuses on changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), which measures the severity of dementia.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Dose level 2 bepranemabExperimental Treatment1 Intervention
Participants randomized to this arm will receive pre-specified doses (Dose level 2) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
Group II: Dose level 1 bepranemabExperimental Treatment1 Intervention
Participants randomized to this arm will receive pre-specified doses (Dose level 1) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
Group III: Placebo ArmPlacebo Group2 Interventions
Participants randomized to this arm will receive Placebo to maintain the blinding during the Double-blind Treatment Period and will re-randomized during the Open-label Extension Period to receive pre-specified doses of bepranemab.

Find a Clinic Near You

Who Is Running the Clinical Trial?

UCB Biopharma SRL

Lead Sponsor

Trials
118
Recruited
23,200+

Jean-Christophe Tellier

UCB Biopharma SRL

Chief Executive Officer since 2015

MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD

Dr. Iris Loew-Friedrich

UCB Biopharma SRL

Chief Medical Officer since 2014

MD from University of Leuven, PhD in Medical Sciences from University of Leuven

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security